DiaMedica Presents at Stroke Conference

DiaMedica Therapeutics, a biopharmaceutical firm listed on Nasdaq (DMAC), is advancing its clinical trials for DM199, a treatment for acute ischemic stroke (AIS). The company has detailed its plans for the ReMEDy2 trial, a pivotal phase 2/3 study, in a poster presentation at the American Heart Association's 2024 International Stroke Conference in Phoenix, AZ. The event, set for February 7-9, 2024, will feature DiaMedica's research in Poster Hall 5-6, with the poster titled "Phase 2/3 Adaptive Design, Randomized Double-blind Placebo-controlled Study To Evaluate The Safety And Efficacy Of Dm199 For The Treatment Of Acute Ischemic Stroke (ReMEDy2 Trial)". The presentation is scheduled for February 8, 2024, from 7:00 PM to 7:30 PM, with Dr. Scott Kasner, the principal investigator of the ReMEDy2 trial, available for inquiries.
In addition to the poster presentation, DiaMedica will have a booth (#1021) at the main hall of the conference for further engagement. The company is dedicated to developing DM199, a recombinant form of the KLK1 protein, which has been used in Asia for treating AIS and other vascular conditions. DiaMedica is focused on enhancing the quality of life for individuals with serious medical conditions, particularly AIS.